Neomycin


Description

A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). Neomycin is a bactericidal aminoglycoside antibiotic that binds to the 30S ribosome of susceptible orga...

Read more

Pharmacology

Indication

Topical uses include treatment for superficial eye infections caused by susceptible bacteria (used i... Read more

Pharmacodynamic

Neomycin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribos... Read more

Mechanismofaction

Aminoglycosides like neomycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Spe... Read more

Absorption

Poorly absorbed from the normal gastrointestinal tract. Although only approximately 3% of neomycin i... Read more

Proteinbinding

Protein binding studies have shown that the degree of aminoglycoside protein binding is low and, dep... Read more

Volumeofdistribution

Information currently not available.

Clearance

Information currently not available.

Halflife

2 to 3 hours

Routeofelimination

The small absorbed fraction is rapidly distributed in the tissues and is excreted by the kidney in k... Read more

Toxicity

LD50 = 200 mg/kg (rat). Because of low absorption, it is unlikely that acute overdosage would occur... Read more


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Conjunctival erythema US
Varying Reports
Swelling US
Varying Reports
Itching US
Varying Reports
Anaphylaxis US
Varying Reports
Local irritation on instillation US
Varying Reports
Skin Sensitization US
Clinical Trial
Ototoxicity US
Clinical Trial
Nephrotoxicity US
Clinical Trial
Skin Sensitization US
Varying Reports
Irritation of the urinary bladder mucosa US
Varying Reports
Ototoxicity US
Varying Reports
Nephrotoxicity US
Varying Reports
Nausea US
Varying Reports
Vomiting US
Varying Reports
Diarrhea US
Varying Reports
Neuromuscular blockage US
Varying Reports
Malabsorption Syndrome US
Varying Reports

Contraindications

  • Route:
    • Oral
  • Regions: US
  • Patient Conditions:
      • Name: Ulcerative gastrointestinal disease
      • Drugbank Id: DBCOND0108136
  • Route:
    • Oral
  • Regions: US
  • Patient Conditions:
      • Name: Inflammatory gastrointestinal disease
      • Drugbank Id: DBCOND0108135
  • Route:
    • Oral
  • Regions: US
  • Patient Conditions:
      • Name: Intestinal Obstruction
      • Drugbank Id: DBCOND0031423
  • Route:
    • Irrigation
    • Ureteral
  • Dose Form:
    • Solution
  • Hypersensitivity:
    • aminoglycosides
  • Regions: US
  • Route:
    • Auricular (otic)
  • Regions: US
  • Patient Conditions:
      • Name: Cutaneos viral infection
      • Drugbank Id: DBCOND0108134
  • Route:
    • Auricular (otic)
  • Regions: US
  • Patient Conditions:
      • Name: External auditory canal disorder
      • Drugbank Id: DBCOND0108014

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Neomycin

The risk or severity of bleeding can be increased when Neomycin is combined with (R)-warfarin.
The risk or severity of bleeding can be increased when Neomycin is combined with (S)-Warfarin.
The risk or severity of bleeding can be increased when Neomycin is combined with 4-hydroxycoumarin.
Neomycin may decrease the excretion rate of Abacavir which could result in a higher serum level.
The metabolism of Acarbose can be decreased when combined with Neomycin.
The risk or severity of nephrotoxicity can be increased when Aceclofenac is combined with Neomycin.
The risk or severity of nephrotoxicity can be increased when Acemetacin is combined with Neomycin.
The risk or severity of bleeding can be increased when Neomycin is combined with Acenocoumarol.
Neomycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
The therapeutic efficacy of Acetylcholine can be decreased when used in combination with Neomycin.
The risk or severity of adverse effects can be decreased when Neomycin is combined with Acetyldigitoxin.
The serum concentration of Acetyldigoxin can be decreased when it is combined with Neomycin.
The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Neomycin.
Neomycin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Neomycin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Neomycin may decrease the excretion rate of Acyclovir which could result in a higher serum level.
The risk or severity of nephrotoxicity can be increased when Neomycin is combined with Adefovir.
The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Neomycin.
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Neomycin.
Neomycin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.

References

  • 1 . Lechevalier HA: The 25 years of neomycin. CRC Crit Rev Microbiol. 1975 May;3(4):359-97. [PubMed: 1095304]
  • 2 . Neomycin Opthalmic FDA Label [File]
  • 3 . Neomycin Irrigation Solution FDA Label [File]
  • 4 . Neomycin Otic FDA Label [File]
  • 5 . Neomycin Tablet FDA Label [File]

Recent Questions